Abstract: Disclosed is a method for producing regulatory T cells, the method comprising: (1) differentiating cells that can differentiate into regulatory T cells, into which an expression construct is introduced, into regulatory T cells, the expression construct comprising: (a) conserved non-coding sequence (CNS) 1, CNS2, and CNS3 of Foxp3 gene; (b) a promoter; and (c) a nucleic acid encoding FOXP3. Also disclosed are regulatory T cells obtained by the method, and a pharmaceutical composition comprising the regulatory T cells.

Abstract: A pump unit includes a pump and a metal ion trap. The pump includes a metal member that comes into contact with a mobile phase. The pump pumps a mobile phase through a flow path. The metal ion trap includes a filter element. The filter element includes a metal ion retention structure for retaining metal ions by interacting with the metal ions included in a mobile phase. The filter element is provided in the flow path for a mobile phase pumped by the pump. The pump unit may be provided in a chromatograph.

Abstract: The present invention measures, with high sensitivity, the phase difference between a plurality of physical fields. A phase difference measurement device (10) comprises: an electromagnetic irradiation unit (2) that repeatedly irradiates a quantum sensor element (1) with electromagnetic waves for manipulating an electron spin state of the quantum sensor element (1) which changes via interaction with a second physical field or a first physical field generated by an AC signal; and a phase difference measurement unit (3) that acquires a plurality of electron spin states after interaction with the second physical field or the first physical field, and measures the phase difference between a plurality of physical fields on the basis of the acquired plurality of electron spin states.

Abstract: A radiation detector includes a substrate including a first electrode portion, a radiation absorption layer disposed on one side with respect to the substrate and configured of a plurality of perovskite crystals, and a second electrode portion disposed on the one side with respect to the radiation absorption layer and being opposite to the first electrode portion with the radiation absorption layer interposed therebetween. Each of the plurality of perovskite crystals is formed to extend with a first direction in which the first electrode portion and the second electrode portion are opposite to each other as a longitudinal direction in a region between the first electrode portion and the second electrode portion in the radiation absorption layer.

Abstract: A grating coupler includes a grating including a plate-shaped base member and modified refractive index regions having a refractive index different from that of the base member and either being point-like and periodically disposed two-dimensionally or one-dimensionally in the base member, or being linear and periodically disposed one-dimensionally in the base member, where the modified refractive index regions each have a planar shape in which a ratio |?2|/|?1| of an absolute value |?2| of a second coupling coefficient to an absolute value |?1| of a first coupling coefficient is 3 or more, the first coupling coefficient being an index indicating intensity at which light traveling in a first direction parallel to the base member is reflected in a second direction different by 180° from the first direction, the second coefficient being an index indicating intensity at which light traveling in the second direction is reflected in the first direction.

Abstract: Provided is a testing method using a biomarker for prediction of success or failure of induction of labor, prediction of preterm birth, and prediction of preterm labor, which can be performed with high reliability, simply, and non-invasively. The testing method of the present invention is a testing method using an expression level of 15-PGDH as an index for success or failure of induction of labor, the testing method including a step of detecting the expression level of 15-PGDH in a specimen, the specimen being a vaginal secretion.

Abstract: A method for enhancement innate immunity is provided. In one aspect, the present disclosure relates to a method for enhancing an innate immune response of a subject or a cell, the subject or the cell being a subject or a cell having an innate immune response that a gene to be subjected to splicing participates in, and this method includes administering a compound that affects alternative splicing to a subject or a cell, or bringing a compound that affects alternative splicing into contact with the subject or the cell.

Abstract: A liquid (30) containing a virus passes through a solid phase (10) made of a polymer having a hydrophobic group to cause the solid phase (10) to retain viruses (40), and then an organic solvent (70) causes the viruses (40) to be eluted from the solid phase (10). As a result, it is possible to rapidly concentrate a virus sample at a high concentration rate.

Abstract: The present invention provides a culture method of cells and/or tissues including culturing cells and/or tissues in a suspended state by using a medium composition wherein indeterminate structures are formed in a liquid medium, the structures are uniformly dispersed in the solution and substantially retain the cells and/or tissues without substantially increasing the viscosity of the solution, thus affording an effect of preventing sedimentation thereof, and the like

Abstract: The present disclosure provides a cerebral organoid derived from a human pluripotent stem cell, a cell aggregate including a cerebral cortical cell, and a method for producing any of them, each being useful for regenerative therapy.

Abstract: A substrate 1 includes a color center excited by excitation light, and at least a pair of reflection members 21a, 21b are arranged with gaps from the substrate 1. The substrate 1 causes the excitation light entering the substrate 1 to exit through its surfaces without reflection, and the reflection members 21a, 21b cause the exited excitation light to reflect at the reflection surface 21-1 or 21-2 and enter the substrate 1, and cause the excitation light to repeatedly enter and exit the substrate 1 and thereby pass through the substrate 1 only a predetermined number of times. Here, the irradiating device 4 emits the excitation light such that the excitation light is incident to the reflection surface 21-1 or 21-2 with an angle perpendicular to one axis among two axes of the reflection surface 21-1 or 21-2 and with a predetermined slant angle from the other axis.

Abstract: The present disclosure provides a composition for ameliorating a skin tissue abnormality comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof.

Abstract: The present invention provides a cardiomyocyte maturation promoter. The present invention provides a cardiomyocyte maturation promoter comprising one or more compounds selected from 2-methoxy-5-((Z)-2-(3,4,5-trimethoxyphenyl)vinyl)phenol, (1-ethyl-1H-benzotriazol-5-yl)methyl (2-(2-methoxy-4-methylphenyl)-4-methyl-1,3-thiazol-5-yl)carbamate, (2?beta)-22-oxovincaleukoblastine, 2-(2-(4-chlorophenyl)ethyl)-6-(2-furyl)-3H-imidazo[4,5-b]pyridine, 4,5-anhydro-1,2-dideoxy-4-methyl-2-((N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl)amino)-1-phenyl-L-threo-pent-3-ulose, 3-(3-methoxyphenyl)-N7,N7-dimethylisoquinoline-1,7-diamine, methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate, 2?-(4-aminophenyl)-1H,1?H-2,5?-bibenzimidazol-5-amine, and salts thereof.

Abstract: A first open/close valve (12a), a drip chamber (14), and a variable valve (17) are provided in this order on a first flow path (10a) from a first connector (11a) side toward a downstream connector (19) side. A second flow path (10b), on which a second open/close valve (12b) is provided, is connected to a section of the first flow path between the first open/close valve and the drip chamber. A priming method includes a first step of causing the first liquid to flow from a first container (20a) into the first flow path and priming the first flow path using the first liquid, and a second step of causing the second liquid to flow from a second container (20b) into the second flow path and priming the second flow path using the second liquid. In the second step, the second liquid moves air that has been present in the second flow path toward the first container (20a).

Abstract: The invention provides an in vitro method of improving the efficiency of establishment of induced pluripotent stem (iPS) cells. The method comprises contacting an isolated somatic cell being reprogrammed into an iPS cell with an inhibitor of p53 function. The invention also provides an in vitro method of producing iPS cells. The method comprises bringing (a) nuclear reprogramming substances or nucleic acids encoding the nuclear reprogramming substances and (b) an inhibitor of p53 function into contact with a somatic cell.

Abstract: Disclosed is a eutectic mixture containing a first component and a second component as main components. The first component is a quaternary ammonium salt, and the second component is an aminocarboxylic acid and/or a derivative thereof, the aminocarboxylic acid having a —COOH group and an —NH— group in the same molecule. The eutectic mixture has a melting point, Tm, which is lower than the melting point of the first component, T1, and which is lower than the melting point of the second component, T2. The eutectic mixture is in a homogeneous liquid state at a temperature higher than the melting point, Tm. Disclosed is a liquid composition containing a third component dissolving in the eutectic mixture. The third component contains one or two or more selected from cellulose, hemicellulose, and lignin.

Abstract: A photonic crystal surface-emitting laser includes a light emitting region from which light is emitted in a direction crossing an in-plane direction, and a current blocking region that is adjacent to the light emitting region in the in-plane direction and in which current is less likely to flow than in the light emitting region. The light emitting region and the current blocking region each include a photonic crystal layer. The photonic crystal layer has a first region and second regions periodically arranged in the first region. A refractive index of each of the second regions is different from that of the first region. The light emitting region includes a first semiconductor layer, an active layer, and a second semiconductor layer. The first semiconductor layer, the active layer, and the second semiconductor layer are sequentially stacked on top of one another in an emission direction of the light.

Abstract: The present invention provides peptides, salts thereof, peptide conjugates, and salts thereof having an anxiolytic-like effect, for example a peptide comprising any amino acid sequence selected from (i) an amino acid sequence SYLPPLTT (SEQ ID NO: 1), (ii) an amino acid sequence YHIEPV (SEQ ID NO: 2), (iii) an amino acid sequence YLLVK (SEQ ID NO: 3), (iv) an amino acid sequence SYLPPLT (SEQ ID NO: 4), (v) an amino acid sequence FLLVK (SEQ ID) NO. 5), and (vi) an amino acid sequence WLLVK (SEQ ID NO: 6).

Abstract: New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.

Abstract: The present invention provides a novel combination therapy with PD-1 blockade therapy. A pharmaceutical composition which comprises a substance capable of enhancing T cell receptor (TCR) signaling and is administered before, after or simultaneously with the administration of a PD-1 signaling inhibitor. A drug which enhances PD-1 signaling inhibitory activity, comprising a CD45 inhibitor and/or a cell. A TCR signaling enhancer comprising a CD45 inhibitor and/or a cell.